Get started
Author

Francesco Agustoni

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
2020 · Marina Chiara Garassino, Jennifer G Whisenant, et al. · The Lancet Oncology · 620
The Clinical Value of Nutritional Care before and during Active Cancer Treatment
2021 · Giuseppe Aprile, Debora Basile, et al. · Nutrients · 141
PDF
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
2024 · Riccardo Gerosa, Rita De Sanctis, et al. · Critical Reviews in Oncology/Hematology · 107
PDF
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin
2017 · P. Bossi, D. Cortinovis, et al. · Annals of Oncology · 89
PDF
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis
2018 · Francesco Agustoni, Kenichi Suda, et al. · Cancer Treatment Reviews · 61
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations
2014 · Eva Regina Haspinger, Francesco Agustoni, et al. · Critical Reviews in Oncology/Hematology · 56
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
2021 · Alessio Bruni, Vieri Scotti, et al. · Frontiers in Oncology · 53
PDF
Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders
2013 · Francesco Agustoni, Marco Platania, et al. · Cancer Treatment Reviews · 46
PDF
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
2021 · A. Lasagna, F. Agustoni, et al. · ESMO Open · 40
PDF
Radiomics features as predictive and prognostic biomarkers in NSCLC
2020 · Chandra Bortolotto, Andrea Lancia, et al. · Expert Review of Anticancer Therapy · 40
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
2015 · Luigi Celio, Monica Niger, et al. · Core evidence · 38
PDF
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
2025 · Alessio Cortellini, Leonardo Brunetti, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib
2019 · Geeta G. Sharma, Diego Cortinovis, et al. · Journal of Thoracic Oncology · 30
PDF
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study
2020 · Andrea Luciani, Antonio Marra, et al. · Clinical Lung Cancer · 29
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors
2014 · D. Serpico, A. Trama, et al. · Annals of Oncology · 29
PDF
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
2023 · Francesco Passiglia, Maria Lucia Reale, et al. · Lung Cancer · 25
PDF
Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial
2011 · Luigi Celio, Angela Denaro, et al. · The Journal of Supportive Oncology · 24
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
2022 · Jennifer G. Whisenant, Javier Baena, et al. · Journal of Thoracic Oncology · 21
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
2021 · A. Lasagna, D. Lilleri, et al. · ESMO Open · 21
PDF
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)
2023 · Stefano Cavalieri, Viviana Vitolo, et al. · Future Oncology · 20
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling
2022 · Riccardo Caccialanza, Emanuele Cereda, et al. · BMC Cancer · 17
PDF
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non–Small-Cell Lung Cancer: The Never-Ending Story
2013 · Francesco Gelsomino, Francesco Agustoni, et al. · Journal of Clinical Oncology · 17
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC
2021 · Fred R. Hirsch, Mary W. Redman, et al. · Clinical Lung Cancer · 15
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma
2021 · Sara Lettieri, Chandra Bortolotto, et al. · Journal of Clinical Medicine · 15
PDF
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study
2025 · A.R. Filippi, M.R. García Campelo, et al. · ESMO Open · 14
PDF
Works count: 124
Citation count: 1,919
H-index: 20
I10-index: 35
Year
Topic
Type